News coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.2368983608997 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Several equities analysts have recently commented on the stock. Cantor Fitzgerald set a $15.00 price target on shares of Progenics Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, March 8th. BidaskClub upgraded shares of Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 8th. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Finally, ValuEngine lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $12.35.

Shares of Progenics Pharmaceuticals (NASDAQ PGNX) opened at $8.28 on Wednesday. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.74. Progenics Pharmaceuticals has a 52 week low of $4.60 and a 52 week high of $11.72. The stock has a market cap of $581.83, a price-to-earnings ratio of -11.34 and a beta of 3.12.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). Progenics Pharmaceuticals had a negative net margin of 436.08% and a negative return on equity of 87.30%. The business had revenue of $3.90 million during the quarter, compared to analyst estimates of $3.18 million. During the same quarter in the previous year, the business earned ($0.10) EPS. Progenics Pharmaceuticals’s quarterly revenue was down 15.2% compared to the same quarter last year. research analysts forecast that Progenics Pharmaceuticals will post -0.59 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Progenics Pharmaceuticals (PGNX) Receives Media Impact Rating of 0.24” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/03/14/progenics-pharmaceuticals-pgnx-receives-media-impact-rating-of-0-24.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Insider Buying and Selling by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.